342 related articles for article (PubMed ID: 30771430)
1. Milk exosomes - Natural nanoparticles for siRNA delivery.
Aqil F; Munagala R; Jeyabalan J; Agrawal AK; Kyakulaga AH; Wilcher SA; Gupta RC
Cancer Lett; 2019 May; 449():186-195. PubMed ID: 30771430
[TBL] [Abstract][Full Text] [Related]
2. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
Mehta A; Dalle Vedove E; Isert L; Merkel OM
Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
[TBL] [Abstract][Full Text] [Related]
3. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
4. Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.
Yang T; Fogarty B; LaForge B; Aziz S; Pham T; Lai L; Bai S
AAPS J; 2017 Mar; 19(2):475-486. PubMed ID: 27882487
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
[TBL] [Abstract][Full Text] [Related]
7. Arrowtail RNA for Ligand Display on Ginger Exosome-like Nanovesicles to Systemic Deliver siRNA for Cancer Suppression.
Li Z; Wang H; Yin H; Bennett C; Zhang HG; Guo P
Sci Rep; 2018 Oct; 8(1):14644. PubMed ID: 30279553
[TBL] [Abstract][Full Text] [Related]
8. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
9. Exosomes-coated bcl-2 siRNA inhibits the growth of digestive system tumors both in vitro and in vivo.
Tao H; Xu H; Zuo L; Li C; Qiao G; Guo M; Zheng L; Leitgeb M; Lin X
Int J Biol Macromol; 2020 Oct; 161():470-480. PubMed ID: 32531356
[TBL] [Abstract][Full Text] [Related]
10. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
11. Bovine milk-derived exosomes for drug delivery.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2016 Feb; 371(1):48-61. PubMed ID: 26604130
[TBL] [Abstract][Full Text] [Related]
12. Development of siRNA payloads to target KRAS-mutant cancer.
Yuan TL; Fellmann C; Lee CS; Ritchie CD; Thapar V; Lee LC; Hsu DJ; Grace D; Carver JO; Zuber J; Luo J; McCormick F; Lowe SW
Cancer Discov; 2014 Oct; 4(10):1182-1197. PubMed ID: 25100204
[TBL] [Abstract][Full Text] [Related]
13. Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA.
Zhang H; Wang Y; Bai M; Wang J; Zhu K; Liu R; Ge S; Li J; Ning T; Deng T; Fan Q; Li H; Sun W; Ying G; Ba Y
Cancer Sci; 2018 Mar; 109(3):629-641. PubMed ID: 29285843
[TBL] [Abstract][Full Text] [Related]
14. Exosomes from iPSCs Delivering siRNA Attenuate Intracellular Adhesion Molecule-1 Expression and Neutrophils Adhesion in Pulmonary Microvascular Endothelial Cells.
Ju Z; Ma J; Wang C; Yu J; Qiao Y; Hei F
Inflammation; 2017 Apr; 40(2):486-496. PubMed ID: 28000095
[TBL] [Abstract][Full Text] [Related]
15. Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of
Zhao G; Ho W; Chu J; Xiong X; Hu B; Boakye-Yiadom KO; Xu X; Zhang XQ
ACS Appl Mater Interfaces; 2023 Jul; 15(26):31273-31284. PubMed ID: 37354089
[No Abstract] [Full Text] [Related]
16. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
17. Cell-free synthesis of connexin 43-integrated exosome-mimetic nanoparticles for siRNA delivery.
Lu M; Zhao X; Xing H; Liu H; Lang L; Yang T; Xun Z; Wang D; Ding P
Acta Biomater; 2019 Sep; 96():517-536. PubMed ID: 31284098
[TBL] [Abstract][Full Text] [Related]
18. Exosomes are natural carriers of exogenous siRNA to human cells in vitro.
Shtam TA; Kovalev RA; Varfolomeeva EY; Makarov EM; Kil YV; Filatov MV
Cell Commun Signal; 2013 Nov; 11():88. PubMed ID: 24245560
[TBL] [Abstract][Full Text] [Related]
19. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
20. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
